A new George Church start­up rais­es $16M. The first-time founders have a ‘crazy vi­sion’ to bring ML to cell ther­a­py

By her own ad­mis­sion, Eliz­a­beth Wood is far from a typ­i­cal biotech CEO.

Fit­ting­ly, she’s build­ing an un­con­ven­tion­al start­up in JU­RA Bio, which an­nounced on Thurs­day a $16.1 mil­lion seed round to bring ma­chine learn­ing in­to de­vel­op­ing cell ther­a­pies. Wood co-found­ed JU­RA back in 2017 along­side Julie Norville, an MIT bio­engi­neer­ing PhD who is JU­RA’s chief tech­nol­o­gy of­fi­cer.

The Har­vard bi­ol­o­gist George Church is al­so a founder, telling End­points News he ex­pects JU­RA to play a role in an “amaz­ing rev­o­lu­tion” that ap­plies ma­chine learn­ing to com­plex li­braries of drug can­di­dates. He says JU­RA is one of six biotechs he has found­ed around that theme. Oth­ers in­clude Shape Ther­a­peu­tics for RNA edit­ing, Dyno Ther­a­peu­tics on op­ti­miz­ing AAV vec­tors, Nabla Bio for de­sign­ing an­ti­bod­ies, and Man­i­fold Bio for pro­tein ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER